Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report.

ABSTRACT: Treatment-resistant schizophrenia (TRS) poses significant therapeutic challenges due to persistent symptoms, poor adherence, and high relapse rates. Long-acting injectable (LAI) antipsychotics offer a promising approach, yet limited evidence exists regarding the combination of two LAI formulations. We report the case of a 62-year-old woman with TRS, characterized by recurrent hospitalizations and inadequate responses to oral and monotherapy treatments. During her latest hospitalization, she received alternating intramuscular administrations of haloperidol decanoate (100 mg/28 days) and aripiprazole (400 mg/28 days). The dual LAI strategy resulted in a marked improvement in psychotic symptoms, functional recovery, and treatment adherence, with no reported side effects. This case highlights

SUBMITTER: Cipolla S 

PROVIDER: S-EPMC11941564 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature